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Scientific report:
Transforming  growth  factor  betas  (TGF-βs)  are  multifunctional  cytokines  that  affect  cell 
proliferation, differentiation, and extracellular matrix formation in a variety of tissues (Burt 
and Law 1994). There are three separate genes encoding TGF-β1, -β2, and -β3, respectively 
(Lawrence 1996; Roberts 1998). In the framework of the project, first RT-PCR experiments 
were performed to demonstrate the presence of TGF-βs in the brain. The resulting cDNAs 
were  also  used  to  produce  specific  in  situ  hybridization  probes  for  the  different  TGF-β 
subtypes (Dobolyi 2009b).
To  understand the  diverse  functions  of  TGF-βs  in  the  brain,  we  described  the 
topographical distribution of mRNAs of the 3 subtypes of TGF-βs by in situ hybridization 
histochemistry in the rat (Dobolyi  et al. 2009; Vincze et al.  2010b). TGF-β1, 2, and 3 all 
demonstrated relatively widespread mRNA expression in various brain areas. Nevertheless, 
the presence  of  their  mRNAs was restricted  to  specific  brain regions  suggesting spatially 
regulated expression in the brain. In some brain areas, including brainstem motoneuron pools 
and the area postrema, the 3 subtypes had similar expression patterns. In most brain areas, 
however,  their  distributions  were markedly different.  In the cerebral  cortex,  TGF-βs were 
expressed in different layers.  In the hippocampus, TGF-β1 was expressed in every region, 
TGF-β2 was abundantly expressed only in the dentate gyrus while TGF-β3 in the CA2 region 
and the dentate gyrus. In the cerebellum, TGF-β1 was expressed in all layers, TGF-β2 was 
abundantly expressed only in the Purkinje cell layer while TGF-β3 mRNA was not present in 
the cerebellum. In addition, many brain regions expressed only a single type of TGF-β. For 
example, the medial preoptic area, the paraventricular hypothalamic and central amygdaloid 
nuclei  contained  only  TGF-β1  mRNA.  The  medial  mamillary  nucleus,  the  parafascicular 
thalamic nucleus and the choroid plexus expressed only TGF-β2 while the reticular thalamic 
nucleus, the superior colliculus, and the inferior olive contain exclusively TGF-β3 mRNA. 
These  results  demonstrated  that  TGF-βs  are  expressed  in  the  rat  brain  and  that  the 
topographical  distributions  of  TGF-βs  are  characteristic  of  the  particular  type  of  TGF-β 
suggesting that they play a role in specific brain functions. The paper reporting these data has 
been published (Vincze et al. 2010b). Therefore, we only present the distribution of TGF-β2 
in some brain regions as an example (Fig. 1).
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Fig.  1.  Dark-field  photomicrographs  of  in  situ  hybridization  sections  demonstrate  the 
expression of mRNA of TGF-β2 in A: cerebral cortex and hippocampus, B: the parafascicular 
thalamic nucleus and the choroid plexus, C: midbrain raphe nuclei, D: midline thalamic nuclei 
and  the  choroid  plexus,  F:  the  medial  subdivision  of  the  medial  mamillary  nucleus,  G: 
superior olive, H: locus coeruleus, pontine tegmental nuclei and the cerebellum. White dots 
represent the presence of TGF-β2 mRNA. The framed area in panel B is magnified in E in 
bright-field to show individual autoradiography grains above cell bodies. Abbreviations: aq - 
cerebral aqueduct, cc – corpus callosum, chp – choroid plexus, DG – dentate gyrus, DR – 
dorsal  raphe  nucleus,  fr  –  fasciculus  retroflexus,  LC  –  locus  coeruleus,  ML  –  lateral 
subdivision  of  the  medial  mamillary  nucleus,  MM  –  medial  subdivision  of  the  medial 
mamillary  nucleus,  MnR  –  median  rephe  nucleus,  PAG  –  periaqueductal  gray,  PC  – 
paracentral thalamic nucleus, PDTg – posterodorsal tegmental nucleus, PF – parafascicular 
thalamic  nucleus,  Pn  –  pontine  nuclei,  PVT  –  paraventricular  thalamic  nucleus,  py  – 
pyramidal tract, Rt – reticular thalamic nucleus, RtTg – reticulotegmental nucleus, SuMM – 
supramamillary  nucleus,  SOC –superior  olivary complex,  V.  –  fifth  layer  of  the  cerebral 
cortex, VI. – sixth layer of the cerebral cortex, 3V – third ventricle.
Spatially restricted, distinct localizations of the individual subtypes of TGF-βs suggest 
their separate, specific functions. To further establish potential functions of TGF-βs, we made 
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attempts to identify the neuronal types that express of TGF-βs. TGF-β1 and TGF-β binding 
protein  1 are  abundantly  expressed  in  the  preoptic  area  of  the  hypothalamus,  which  is  a 
central element of the brain circuitry regulating maternal behaviors (Gray and Brooks 1984; 
Numan 1986; Lonstein et al. 1998; Stack and Numan 2000; Simerly 2002; Numan 2006). In 
the framework of the project, we published that the neurochemical characteristics of preoptic 
neurons  change  in  mother  rats  as  demonstrated  by  the  dramatic  induction  of  some 
neuropeptides  including  amylin  and  tuberoinfundibular  peptide  of  39  residues  in  the 
postpartum  period  (Dobolyi  2009a;  Cservenak  et  al.  2010;  Dobolyi  et  al.  2010b).  The 
distribution of TGF-β1 is the same as that of amylin-expressing cell bodies (Fig. 2) and fiber  
terminals containing tuberoinfundibular peptide of 39 residues in the preoptic area (Dobolyi 
2009a; Cservenak et al. 2010; Dobolyi et al. 2010b). We provided preliminary evidence that 
the expression level of TGF-β induced protein is elevated in the preoptic area of rat dams. 
Given  the  expected  role  of  TGF-βs  in  the  regulation  of  neuronal  plasticity  in  endocrine 
regulations we suggest that TGF-β1 may play a role in maternal alterations in the preoptic 
area (Dobolyi et al. 2010a).
Fig. 2. Demonstration of the similarity between the distributions of TGF-β1 and maternally 
induced amylin in the preoptic area of the hypothalamus. A. A coronal section of the preoptic 
area  is  shown  by  Luxol-cresyl-violet  staining.  B:  A  dark-field  photomicrograph  of  the 
preoptic area of a section hybridized with TGF-β1.  C: A dark-field photomicrograph of the 
preoptic area of a section hybridized with amylin. Abbreviations: ac – anterior commissure, 
BNSTv – ventral subdivision of the bed nucleus of the stria terminalis, f – fornix, MPN – 
medial preoptic nucleus, och – optic chiasm, 3V – third ventricle.
To further identify brain regions and cell types that express TGF-βs, neuronal markers were 
identified in different hypothalamic, thalamic, hippocampal, and cortical brain regions. Since 
we had preliminary data  using double in  situ  hybridization  that  TGF-β binding protein  2 
mRNA is expressed in the perifornical / lateral  hypothalamic area (Dobolyi  and Palkovits 
2008),  we  developed  an  antibody  against  this  binding  protein  and  performed  double 
immunohistochemistry  using  this  antibody  and  markers  of  neurons  located  in  this 
hypothalamic area. We showed that TGF-β binding protein 2 immunoreactivity is present in 
orexin  neurons  but  not  in  melanin-concentrating  hormone-containing  neurons  in  the 
hypothalamus (Fig. 3).
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Fig.  3. TGF-β binding protein 2-immunoreactive neurons in the perifornical  /  dorsolateral 
hypothalamic area of a colchicines treated rat brain. A: The distribution of TGF-β binding 
protein  2  immunolabeling  in  the  hypothalamus.  B:  A  high  magnification  confocal 
photomicrograph indicates the accumulation of TGF-β binding protein 2 immunoreactivity 
into granules within cell bodies. C: TGF-β binding protein 2 immunoreactivity is co-localized 
with orexin A-immunoreactivity in neurons of the perifornical / dorsolateral  hypothalamic 
area.  The number  of  single labeled  cells  is  very low compared  to  the  number  of  double 
labeled ones. D: In contrast, melanin-concentrating hormone (MCH) immunoreactivity does 
not co-localize with TGF-β binding protein 2 immunoreactivity.
Among the potential neuronal functions of TGF-βs, their involvement in neuroprotection is 
the best established (Gross et al. 1993; Prehn et al. 1993; Ruocco et al. 1999; Zhu et al. 2002). 
TGF-β1  administered  into  the  brain  reduces  the  infarct  size  in  experimental  models  of 
ischemia. To make a step forward towards understanding the role of endogenous TGF-β in 
neuroprotection,  we induced  focal  brain  ischemia  with  unilateral  occlusion  of  the  middle 
cerebral  artery  to  establish  expressional  changes  of  the  different  subtypes  of  TGFbetas 
following an ischemic  attack.  Focal  ischemia  affected the expression patterns  of  TGF-βs. 
Within the infarct area, the TGF-β mRNA levels declined. In contrast, the expression of all 3 
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types  of  TGF-βs  was  induced  outside  the  infarct  area.  There  were,  however,  significant 
differences between the TGF-β subtypes in the spatial pattern of increased expression (Fig. 4). 
TGF-β1  showed  elevated  expression  level  throughout  the  penumbra.  In  contrast,  mRNA 
levels of TGF-β2 and 3 were increased only in layers II., III., and V. of the cerebral cortex  
ipsilateral  to  the  ischemic  lesion.  In  these layers,  however,  the  induced expressions  were 
present  even  as  far  from  the  infarct  area  as  the  midline.  In  contrast,  the  contralateral 
hemisphere showed no labeling for TGF-β2 and 3 in layers II., and III.  These results suggest 
that  TGF-βs  are  involved  in  the  response  of  the  brain  tissue  to  ischemic  insult  but  the 
individual subtypes have different roles in the process (Vincze et al. 2010a).
Fig.  4.  Dark-field  photomicrographs  of  in  situ  hybridization  sections  demonstrate  the 
induction  of  mRNA  of  TGF-βs  by  middle  cerebral  artery  occlusion  (MCAO).  A:  TTC 
staining demonstrates the effect of ischemia on brain tissue. The infarct area is indicated by 
star symbol (*). As indicated in other panels, the infarct area does not contain mRNA of any 
of the TGF-βs. B: TGF-β1 expression is induced in the penumbra of the ischemic area. C, A 
bright-field  photomicrograph  of  the  brain  area  indicated  by  the  white  arrow  in  panel  B 
demonstrates  individual  autoradiography  grains  above  cell  bodies  expressing  TGF-β1.  D: 
TGF-β2 expression is induced in layers II., III., and V. of the ipsilateral cerebral cortex. The 
induction is particularly salient in layers II. and III. where no significant labeling is present in 
the contralateral hemisphere. Also see that different sublayers of layer V. contain TGF-β2. E: 
A bright-field photomicrograph of the brain areas indicated by the arrow in panel D shows 
individual autoradiography grains above cell bodies expressing TGF-β2.
Continuing this line of research, we also investigated the time course of the induction for each 
individual TGF-β subtype.  The mRNA levels of TGF-βs was only slightly changed 3h after 
MCAO. TGF-β1, which we showed is expressed in the penumbral region of the infarct area 
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24 hours after the lesion, was present within the lesioned tissue 6 hours after the occlusion. In 
contrast, TGF-β2 and 3, which appear in specific layers of the cerebral cortex throughout the 
hemisphere ipsilateral to the lesion, are already present in these sites 6 hours after the lesion 
albeit with a lower level of expression than 24 hours after the lesion. The expression patterns 
72h after the lesion were similar to that 24h after MCAO. These data were submitted as an 
abstract to the 15th Congress of the European Federation of Neurological Societies (Pál et al. 
2011b), and will form part of a research article on the induction of TGF-βs following MCAO.
To characterize the mechanisms how the induction of the different types of TGF-βs occurs, 
immediate  early  gene  expression  was  investigated  following  MCAO  (Pál  et  al.  2011a). 
Interestingly, Fos expression appears in layers 2, 3 and 5 of the cerebral cortex exclusively in 
the hemisphere ipsilateral to the lesion (Fig. 4A). Since this distribution pattern is similar to 
the distribution of TGF-β2 and 3 induced by MCAO, we performed double labeling in a way 
that Fos immunohistochemistry was combined with radioactive in situ hybridization for each 
TGF-β  subtype.  A  co-localization  was  found  between  Fos  and  TGF-β2  and  3  while  we 
observed no TGF-β1 cells  expressing Fos (Fig. 4). These data suggest that the immediate 
early gene Fos contributes to the induction of TGF-β2 and 3 (Pál et al. 2011a). To find out if  
regions of the cerebral cortex remote from the infarct area express Fos and TGF-β2 and 3 by 
means of neuronal connections, we performed transaction of the cortex medial to the expected 
infarct area and will establish if the induction of Fos and TGF-β2 and 3 occurs medial to the 
transactions,  that  is,  if  the  stimulus  for  induction  derived  from the  lesion  can  cross  the 
transection.
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Fig. 4. Fos expression following MCAO. A:  Fos-immunoreactive cell  bodies are apparent 
ipsilateral but not contralateral to the lesion in the cerebral cortex. In addition, the density of 
Fos-ir neurons depends on the particular cortical layer: it is the highest in layer II. The lesion 
is indicated by *. The lesioned and consequently unfixed tissue is damaged and broken. B: 
TGF-β1 mRNA (black grains) does not co-localize with Fos-ir neurons. Black arrows indicate 
single labeled Fos-ir cell bodies. C: TGF-β2 mRNA (black grains) co-localizes with Fos-ir 
neurons.  Double labeled neurons are  indicated by arrowheads.  Abbreviations:  cc -  corpus 
callosum, CP -caudate putamen, LV - lateral ventricle.
We also described the MCAO-induced expression pattern of another immediate early gene, 
the activating transcription factor 3 (ATF3). This protein is a member of the ATF/cyclic AMP 
response element-binding family of transcription factors, and is known to play a role in the 
regulation of cell cycle and apoptosis. Intriguingly, ATF3 is induced in the lesion site within 2 
hours of MCAO and is present in the penumbral region 24 hours after the lesion (Fig. 5A). 
We performed double labeling in a way that ATF3 immunohistochemistry was combined with 
radioactive in situ hybridization for each TGF-β subtype (Pál et al. 2011a). TGF-β1 was found 
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to be co-localized with ATF3 (Fig. 5B) whereas TGF-β2 and 3 mRNA is not present in cells 
containing ATF3 (Pál et al. 2011a).
Fig.  5.  ATF3  expression  following  MCAO.  A:  ATF3-immunoreactive  cell  bodies  are 
abundant around the lesion site in the presumed prenumbra as indicated by arrowheads. B: 
TGF-β1 mRNA (black grains) co-localizes with ATF3-ir neurons (brown). Double labeled 
neurons are  indicated  by arrowheads.  Abbreviations:  cc  -  corpus  callosum,  CP -  caudate 
putamen.
We also showed that  neurons expressing immediate  early genes  (Fos and ATF3)  did not 
contain Fluoro Jade C, a marker of neurodegeneration (Fig. 6). These observations suggest 
that endogenous TGF-β1 and TGF-β2 and 3 all participate in neuroprotection, although they 
are induced by different mechanisms following an ischemic attack. Some of these results have 
been reported in conference abstracts (Pál et al. 2011a). In addition, a manuscript is under 
preparation entitled: ´The mechanisms of the inductions of different TGF-βs following middle 
cerebral artery occlusion in rats´.
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Fig. 6. Immediate early genes are expressed in non-degenerating neurons following MCAO. 
A: Fos expression following MCAO is not present in neurons labeled with Fluoro Jade C, a 
marker of degenerating neurons. B: ATF-3 immunoreactivity is not present in neurons labeled 
with Fluoro Jade C following MCAO.
The glial vs. neuronal character of cells expressing the particular TGF-β subtypes following 
MCAO has been examined. The co-expression of TGF-β with glial and neuronal markers was 
investigated  by  double  in  situ  hybridization  histochemistry  experiments  combining 
radioactive and non-radioactive in situ hybridization. These experiments were not successful. 
The lower sensitivity  of  the non-radioactive  labeling  as  did not  allow us  to  visualize  the 
required  markers.  Therefore,  we chose another  approach and identified  the  types  of  cells 
expressing TGF-β using a combination  of in situ  hybridization with immunocytochemical 
methods (Pál et al. 2011b). NeuN, a neuronal marker, and glial fibrillary acidic protein, a glial 
marker,  were  labeled  with  immunocytochemistry  combined  with  in  situ  hybridization 
histochemistry for TGF-βs (Pál et al. 2011b). We found that all types of TGF-βs were induced 
predominantly in neurons and not glial cells following MCAO (Fig. 7).
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Fig. 7. MCAO induces TGF-β1 in neurons and not in glial cells. A: Black dots representing 
TGF- β1 mRNA are distributed above cells labeled with NeuN immunocytochemistry (brown 
cell bodies). Black arrows show double-labeled neurons. B: Black dots representing TGF- β1 
mRNA are not distributed above cells labeled with GFAP immunocytochemistry (brown cell 
bodies).  Black arrowheads show cells  expressing TGF-β1 mRNA while  white arrowheads 
point to glial cells immunolabeled with GFAP.
In addition to our studies in the rat, we developed in situ hybridization probes specific 
for mouse TGF-βs as well  as TGF-β binding proteins. Two, non-overlapping probes were 
produced  for  each  gene.  These  probes  were  used  in  additional  in  situ  hybridization 
experiments in normal and transgenic mice. Probes against the same mRNA indeed provided 
identical  expression  patterns  demonstrating  their  specificity.  Analysis  of  the  expression 
patterns in mice are under progress. In order to describe the distribution of mRNA of TGF-β 
subtypes  during ontogeny we obtained mouse brains at  different  embryonic  and postnatal 
ages. In situ hybridization was performed and the altering level of expression of TGF-βs in 
particular brain regions during ontogeny described.
Our  subsequent  goal  was  to  examine  the  effect  of  the  absence  of  TGF-β binding 
proteins on the TGF-β system.  Transgenic approaches  provided only a limited  amount  of 
information on the neural functions of TGF-βs because TGF-β knock-out mice die during 
ontogenic development for abnormalities and dysfunctions of peripheral organs (Kulkarni et 
al. 1993; Kaartinen et al. 1995; Sanford et al. 1997). An indirect approach to TGF-β function 
is knocking out TGF-β binding proteins. While TGF-β binding protein 2 knock-out mice die 
in  early gestation  (Shipley et  al.  2000),  mice  lacking TGF-β binding protein  1,  3,  and 4 
hypomorphic mice containing only 2% of the normal level of TGF-β binding protein 4 mRNA 
survive until adulthood (Dabovic et al. 2002; Sterner-Kock et al. 2002; Drews et al. 2008). 
Although these transgenic mice possess various degrees of abnormalities in their peripheral 
organs, they are useful to study the neural functions of TGF-βs. The recently developed TGF-
β binding protein 1 knock-out mice was the best candidate for our studies because these mice 
are viable and fertile, and demonstrate only mild peripheral abnormalities (Drews et al. 2008). 
In  the  framework  of  the  project,  we  obtained  transgenic  mice  from  our our  German 
collaborator, Prof. Dr. Ralf Weiskirchen, Aachen, Germany. The expression patterns of TGF-
βs and their binding proteins were investigated in these mice. The mRNA expression patterns 
12
of TGF-βs and TGF-β binding proteins in TGF-β binding protein 1 knock-out mice were 
compared to that in wild-type littermates. We expected disturbances in the mRNA distribution 
of TGF-βs and TGF-β binding proteins in the mouse line lacking TGF-β binding protein 1. 
However,  no major  difference  in  the  expression  pattern  of  the  investigated  genes  was 
observed except for TGF-β binding protein 1, which was of course not present in the knock-
out mice (Fig.  8). These data  suggest that  TGF-β binding protein  1 expression cannot  be 
replaced by the expression of another subtype of TGF-β binding protein. 
Fig. 8. TGF-β binding protein 3 expression in the septum is not perturbed in mice lacking 
TGF-β binding protein 1. A: TGF-β binding protein 1 expression in the septum in a wild-type 
mouse.  The  distribution  is  abundant  in  the  lateral  septal  nucleus  (LS).  B:  The  in  situ 
hybridization signal disappears in mice lacking TGF-β binding protein 1 as expected. C: TGF-
β  binding  protein  3  expression  in  the  septum in  a  wild-type  mouse.  The  distribution  is 
abundant in the medial septal nucleus (MS). D: TGF-β binding protein 3 expression in the 
septum of a mouse lacking TGF-β binding protein 1. TGF-β binding protein 3 does not appear 
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in the lateral septal nucleus that misses the expression of TGF-β binding protein 1. Additional 
abbreviations: ac – anterior commissure, cc – corpus callosum, LV – lateral ventricle.
Finally, we started to develop in situ hybridization probes specific to human TGF-βs in 
order to describe the presence and distribution of TGF-βs in the human brain. Human brain 
tissue samples have also been obtained for these experiments from the Human Brain Tissue 
Bank  of  the  Neuromorphological  and  Neuroendocrine  Research  Laboratory  of  the 
Semmelweis University and the Hungarian Academy of Sciences. We also started to prepare 
for the investigation of the effect of cerebral infarcts on TGF-β in human. To characterize 
different  human  cerebral  infarcts,  a  multiparametric  non-linear  statistical  analysis  of 
cardiovascular  and  respiratory  alterations  during  extensive  cerebral  infarcts  requiring 
neurointensive care was performed and reported in abstract form (Lovas et al. 2010).
Scientific originality and significance of the results
The critically important role that growth factors play in the development and function of the 
central  nervous  system has  been  studied  by  neuroscientists  for  decades.  A  great  deal  of 
information accumulated on the neural  functions of neurotrophins  including nerve growth 
factor, brain-derived neurotrophic factor, and other neurotraphic factors. Based on our results, 
which demonstrated the localized expression of TGF-βs and their binding proteins in specific 
types of neuronal cells, we concluded the innovative idea that TGF-βs also play an important  
role  in  the  function  of  the  central  nervous  system.  Recent  evidence  provides  initial 
information  on  the  possible  neural  functions  of  TGF-βs.  They  are  neuroprotective  in 
hippocampal pyramidal cells (Dhandapani and Brann 2003), are potent survival factors for 
midbrain  dopaminergic  neurons  (Markus  2007;  Zhang  et  al.  2007),  regulate  neuronal 
differentiation  (Garcia-Campmany  and  Marti  2007),  increase  neurogenesis  in  the  dentate 
gyrus (Battista et al.  2006), modulate plasticity in hippocampal neurons (Fukushima et al. 
2007),  may  participate  in  brain  tumor  formation  (Aigner  and  Bogdahn  2008),  and  may 
directly  influence  autonomic  (Fujikawa  et  al.  2007;  Matsumura  et  al.  2007)  and 
neuroendocrine functions (Bouret et al. 2004; Fevre-Montange et al. 2004). Further functional 
experiments  were  hindered  by  the  lack  of  knowledge  on  the  distribution  of  individual 
subtypes of TGF-βs and their localization in particular cell types.
In the adult rat brain, we first described the presence and distribution of TGF-βs using 
in  situ  hybridization  histochemistry (Vincze  et  al.  2010b).  The distribution  pattern  of  the 
mRNA  of  TGF-βs  resembles  that  of  TGF-β  immunoreactivities  in  most  brain  regions 
(Unsicker  et  al.  1991).  However,  TGF-β1  immunoreactivity  was  reported  to  be  present 
constitutively only in meninges and the choroid plexus in the brain (Unsicker et al. 1991; 
Komuta  et  al.  2009)  but  we  found  a  more  widespread  expression  of  the  mRNA of  this 
subtype. Furthermore, TGF-β2 and -3 immunoreactivities entirely overlapped and, in general, 
were found in large multipolar neurons (Unsicker et al.  1991), the level of TGF-β2 being 
considerably  higher  (Bottner  et  al.  2000).  In  contrast,  we  found  significantly  different 
expression patterns of TGF-β2 and -3 mRNAs. Insofar as the immunoreactivities were found 
in cell bodies rather than fibers, it is not likely that the differences stem from the transport of 
TGF-βs  from  the  cell  bodies.  In  turn,  the  better  sensitivity  and  selectivity  of  in  situ 
hybridization histochemistry could be the underlying reason of the reported differences.
Our results provided the anatomical basis of the already established actions of TGF-βs 
in the central nervous system thereby allowing the design of more specific experiments on the 
functions of individual TGF-β subtypes. In addition, our results on the distribution of TGF-βs 
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suggest the involvement of this system in functions previously not explored. Consequently, 
novel actions of TGF-βs were suggested based on the localization of TGF-βs in neuronal cell 
types previously not involved with this growth factor system. In particular, our results suggest 
that the TGF-β system may be involved in the maternal regulations governed by the preoptic 
area because TGF-β1 and TGF-β binding protein 1 have distributions similar to the neurons 
activated in the preoptic area in response to pup retrieval (Dobolyi and Palkovits 2008; Vincze 
et al. 2010b). Therefore, in the future, we will further investigate the role of the TGF-β system 
in the control of maternal adaptations.
Among  the  potential  neuronal  functions  of  TGF-βs,  their  involvement  in 
neuroprotection is the best established (Flanders et al. 1998; Bottner et al. 2000; Dhandapani 
and Brann 2003). TGF-β1 administered into the brain reduces the infarct size in experimental 
models of ischemia (Gross et al. 1993; Prehn et al. 1993; Zhu et al. 2002) while antagonizing 
the endogenous action of TGF-β1 with the injection of a soluble TGF-β type  II receptor, 
which binds TGF-β1 and prevents its biological actions, resulted in a dramatic increase in 
infarct area (Ruocco et al. 1999).  In the framework of the current application, we established 
the induction of endogenous TGF-βs following focal brain ischemia. In addition, a subtype-
specific  expression  pattern  of  TGF-βs was found suggesting  the involvement  of  different 
TGF-βs in different aspects of neuroprotection. Establishing such roles of endogenous TGF-
βs in neuroprotective mechanisms is particularly important because the brain is vulnerable to 
ischemic insults as most of the neurons cannot be replaced. Ischemic stroke alone is the fourth 
leading cause of death resulting in approximately 480,000 deaths each year  in Europe. In 
addition,  ischemic  stroke  is  a  leading  cause  of  serious,  long-term disability.  Options  for 
prevention  and  treatment  are  very  limited,  necessitating  new  approaches.  Our  results 
describing  the morphological  and neurochemical  changes  of  the  TGF-β system in animal 
models will provide the formation of exploring the TGF-βs system as drug targets creating a 
close link between basic scientific knowledge and potential medical applications to facilitate 
the  development  of  drugs  acting  on  the  TGF-β  system  and  the  investigation  of  their 
effectiveness in alleviation of the consequences of stroke. 
Collectively, the new knowledge gained in the framework of the proposal is expected 
to have a major positive impact on understanding the TGF-β system in the central nervous 
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